Pathomechanisms and hypothesis-guided therapeutic strategies for late-onset Alzheimer's Disease;Pathomechanismen und hypothesengeleitete therapieoptionen bei der spätform der Alzheimer-Krankheit

Fortschritte der Neurologie Psychiatrie

Volumn 71, Issue SUPPL. 1, 2003, Pages

  Hoyer, S ^a   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE;

AGING; ALZHEIMER DISEASE; ARTICLE; CELL FUNCTION; CELL MEMBRANE; DRUG EFFICACY; GERMANY; HUMAN; MYOPATHY; PATHOPHYSIOLOGY; PERSIAN GULF SYNDROME;

EID: 0042156746     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Pericak-Vance M, Haines JL. Genetic susceptibility to Alzheimer disease. Trends Genet 1995; 11: 504-508
2. Tilley L, Morgan K, Kalsheker N. Genetic risk factors in Alzheimer's disease. J Clin Pathol Mol Pathol 1998; 51: 293-304
3. Pericak-Vance MA, Grubber J, Baily LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD et al. Identification of novel genes in late-onset Alzheimer's disease. Exp Geront 2000; 35: 1343-1352
4. Holness MJ, Langdown ML, Sugden MC. Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of type 2 diabetes mellitus. Biochem J 2000; 349: 657-665
5. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20: 154-159
6. Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatment. Science 1997; 275: 630-631
7. Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 2001; 22: 131-146
8. Bancher C, Jellinger K, Lassmann H, Fischer P, Leblhuber F. Correlations between mental state and quantitative neuropathology in the Vienna Prospective Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 1996; 246: 137-146
9. Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging 1993; 14: 589-596
10. Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenyzm A-acetylating enzymes in Alzheimer's disease: possible cholinergic "compartment" of pyruvate dehydrogenase. Neurosci Lett 1980; 18: 105-110
11. Drachman DA, Noffsinger D, Sahakian BJ, Kurdziel S, Fleming P. Aging, memory and the cholinergic system: a study of dichotic listening. Neurobiol Aging 1980; 1: 39-43
12. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 1999; 72: 2278-2285
13. Pettegrew JW, Klunk WE, Panchalingam K, McCLure RJ, Stanley JA. Molecular insights into neurodevelopmental and neurodegenerative diseases. Brain Res Bull 2000; 53: 455-469
14. Rupprecht R, Holsboer F. Neuroactive steroids: mechanism of action and neuropharmacological perspectives. Trends Neurosci 1999; 22: 410-416
15. Dietschy JM, Rürley SD. Cholesterol metabolism in the brain. Curr Op Lipidol 2001; 12: 106-112
16. Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, Bergmann K von, Beyreuther K, Schröder J. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002; 324: 83-85
17. Chang WJ, Rothberg GK, Kamen BA, Anderson RG. Lowering the cholesterol content of MA 104 cells inhibits receptor-mediated transport by folate. J Cell Biol 1992; 118: 63-69
18. Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis and capillary permeability of select macromolecules. J Cell Biol 1994; 127: 1217-1232
19. Smith RM, Harada S, Smith JA, Zhang S, Jarett L. Insulin-induced protein tyrosine phosphorylation cascade and signalling molecules are localized in a caveolin-enriched cell membrane domain. Cell Signal 1998; 10: 355-362
20. Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M, Lindroth M, Peterson KH, Magnusson KE, Stralfors P. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J 1999; 13: 1961-1971
21. Mauch DH, Nägler K, Schumacher S, Göritz EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354-1357
22. Hoyer S, Frölich L, Sandbrink R. Molekulare Medizin der Alzheimer Krankheit. In: Ganten D, Ruckpaul K (Hrsg.). Handbuch der molekularen Medizin, Bd. 5: Erkrankungen des Zentralnervensystems. Berlin-Heidelberg: Springer, 1999: 195-236
23. Müller WE, Mutschler E, Riederer P. Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia. Pharmacopsychiat 1995; 28: 113-124
24. Henneberg N, Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 1995; 21: 63-74
25. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: An update. J Neural Transm 2002; 109: 341-360
26. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frölich L, Bogerts B, Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Letters 1999; 263: 161-164
27. Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 1999; 19: 7300-7308
28. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, Alkon DL. Brain insulin receptors and spatial memory. J Biol Chem 1999; 274: 34893-34902
29. Solano DJ, Sironi M, Bonfini C, Solerte B, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 2000; 14: 1015-1022
30. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneural β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-2570
31. Hoyer S. Senile dementia and Alzheimer's disease: brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 447-478
32. Salehi M, Hodgkins BJ, Merry BJ, Goyns MH. Age-related changes in gene expression in the rat brain revealed by differential display. Experientia 1996; 52: 888-891
33. Wu HC, Lee EHY. Identification of a rat brain gene associated with aging by PCR differential display method. J Mol Neurosci 1997; 8: 13-18
34. Jiang CH, Tsien JZ, Schultz PG, Hu Y. The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci USA 2001; 98: 1930-1934
35. Hoyer S. The effect of age on glucose and energy metabolism in brain cortex of rats. Arch Gerontol Geriatr 1985; 4: 193-203
36. Bowen DM. Cellular aging: selective vulnerability of cholinergic neurons in human brain. Monogr Dev Biol 1984; 17: 42-59
37. Harik SI, McCracken KA. Age-related increase in presynaptic noradrenergic markers of the rat cerebral cortex. Brain Res 1986; 381: 125-130
38. Perego C, Vetrugno CC, De Simono MG, Algeri S. Aging prolongs the stress-induced release of noradrenaline in rat hypothalamus. Neurosci Lett 1993; 157: 127-130
39. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S et al. Insulin and insulin receptors in the brain in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-438
40. Swaab DF, Raadsheer FC, Endert EF, Hofman MA, Kamphorst WC, Ravid R. Increases in cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J Neuroendocrinol 1994; 6: 681-687
41. Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 412-425
42. Igbavboa U, Avdulov A, Schröder F, Wood WG. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 1996; 66: 1717-1725
43. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci 1992; 15: 117-122
44. Subbarao KV, Richardson JS, Hug LC. Autopsy samples of Alzheimer's cortex show increased lipid perpidation in vitro. J Neurochem 1990; 55: 342-345
45. Mesulam MM. Neuroplasticity failure in Alzheimer's disease, bridging the gap between plaques and tangles. Neuron 1999; 24: 521-529
46. Bak P, Tang C, Wiesenfeld K. Self-organized criticality. Phys Rev A 1988; 38: 364-374
47. Held GA, Solina DH, Keane DT, Haag WJ, Horn PM, Grinstein G. Experimental study of critical-mass fluctuations in an evolving sandpile. Physic Rev Lett 1990; 69: 1120-1123
48. Hoyer S, Nitsch R, Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm (P-D Sect) 1991; 3: 1-14
49. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimua J, Yonekura Y, Konichi J. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 1994; 35: 1-6
50. Peskind ER, Elrod R, Dobie DJ, Pascualy M, Petrie E, Jensen C, Brodkin M, Murray S, Veith RC, Raskind MA. Cerebrospinal fluid nonepinephrine in Alzheimer's disease and normal aging. Neuropsychopharmacology 1998; 19: 465-471
51. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 2000; 35: 1363-1372
52. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1988; 105: 415-422
53. Hong M, Lee VMY. Insulin and insulin-like growth factor-1 regulate τ phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-19553
54. Mandelkow EM, Drewes G, Biernat J, Gustke N, Lint J van, Vandenheede JR, Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein τ. FEBS Lett 1992; 314: 315-321
55. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation end products. J Neural Transm 1998; 105: 439-461
56. 14C) glucose in vitro in human neocortex. J Neurochem 1983; 41: 1329-1334
57. Hoyer S. Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol Chem Neuropathol 1992; 16: 207-224
58. Gibson GE, Jope R, Blass JP. Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem J 1975; 148: 17-23
59. 14C) glucose by tissue prisms from human neocortex. Biochem J 1981; 196: 867-876
60. Münch G, Lüth HJ, Wong A, Arendt Th, Hirsch E, Ravid R, Riederer P. Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000; 20: 253-257
61. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 1995; 312: 163-167
62. Röder HM, Ingram VM. Two novel kinases phosphorylate τ and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. J Neurosci 1991; 11: 3325-3343
63. Bush ML. Niyashiro JS, Ingram VM. Activation of a neurofilament kinase, a τ kinase and a τ phosphatase by decreased ATP levels in nerve growth factor-differentiated PC 12 cells. Proc Natl Acad Sci USA 1995; 92: 1962-1965
64. Wilson CA, Doms RW, Lee VMY. Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 1999; 58: 787-794
65. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneural Aβ42 accumulation in human brain. Am J Pathol 2000; 156: 15-20
66. Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT, Growdon JH. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995; 37: 512-518
67. Schröder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp MV, Schad LR, Sandbrink R, Sauer H, Masters CL, Beyreuther K. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry 1997; 2: 505-507
68. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T et al. Longitudinal study of cerebrospinal fluid levels of τ, Aβ1 -40, and Aβ1 -42 (43) in Alzheimer's disease: A study in Japan. Ann Neurol 1998; 44: 17-26
69. Tapiola T, Pirttilä T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H. Three-year follow-up of cerebrospinal fluid τ, β-amyloid 42- and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000; 280: 119-122
70. a Nostrand WE van, Wagner SL, Rodman Shankle W, Farrour JS, Dick M, Rozemüller JM, Kuiper MA, Wolters EC, Zimmermann J, Cotman CW, Cunningham DD. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 1992; 89: 2551-2555
71. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of α- and β-secretase cleared amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 278: 169-172
72. Davidsson P, Bogdanovic N, Lannfeldt L, Blennow K. Reduced expression of amyloid precursor protein, presenilin-1 and rab 3a in cortical brain regions in Alzeimer's disease. Dement Geriatr Cogn Dis 2001; 12: 243-250
73. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 1989; 75: 227-232
74. Hoyer S, Nitsch R, Oesterreich K. Ammonia is endogenously generated in the brain in the presence of presumed and verified dementia of Alzheimer type. Neurosci Lett 1990; 117: 358-362
75. Blandini F, Sand P, Riederer P, Greenamyre JT. Parkinson's Disease-Neuroprotection. In: Lodge D, Danysz W, Parsons G (eds.). Ionotropic glutamate Receptors as Therapeutic Targets. Johnson City, TN: Graham Publishing Co., 2002 in press
76. Scorrano L, Petronilli V, Bernard P. On the voltage dependence of the mitochondrial permeability transition pore - a critical appraisal. J Biol Chem 1997; 272: 12295-12299
77. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm 1996; (Suppl) 47: 73-101
78. Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The Neuronal Calcium Sensor Protein VILIP-1 Is Associated with Amyloid Plaques and Extracellular Tangles in Alzheimer's Disease and Promotes Cell Death and Tau Phosphorylation in Vitro: A Link between Calcium Sensors and Alzheimer's Disease? Neurobiol Dis 2001; 8: 900-909
79. Retz W, Kornhuber J, Riederer P. Neurotransmission and the ontogeny of human brain. J Neural Transm 1996; 103: 403-419
80. Cruz-Sánchez FF, Durany N, Thome J, Riederer P, Zambón D. Correlation between Apolipoprotein-E Polymorphism and Alzheimer's Disease Pathology. J of Alzheimer's Disease 2000; 2: 223-229
81. Retz W, Thome J, Durany N, Harsányi A, Retz-Junginger P, Kornhuber J, Riederer P, Rösler M. Potential genetic markers of sporadic Alzheimer's dementia. Psychiatric Genetics 2001; 11: 115-122
82. Sun FF, Fleming WE, Taylor BM. Degradation of membrane phospholipids in the cultured human astroglial cell line UC-11MG during ATP depletion. Biochem Pharmacol 1993; 45: 1149-1155
83. Nitsch RM, Blusztayn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992; 89: 1671-1675
84. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I. On the turnover of brain cholesterol in patients with Alzheimer's disease. Hormonal induction of the cholesterol - catabolic enzyme CYP 46 in glial cells. Neurosci Lett 2001; 314: 45-48
85. Mason RP, Shoenmaker WJ, Shajenko L, Chambers T, Herbette LG. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 1992; 13: 413-419
86. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, Boom J, van der, Havekes LM. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Ass Disord 1998; 12: 198-203
87. Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, Bergmann K von, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195-198
88. Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Björkhem I, Bergmann K von, Heun R. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker of Alzheimer's disease. NeuroReport 2000; 11: 1959-1962
89. Wu Y, Sun FF, Tong DM. Changes in membrane properties during energy depletion-induced cell injury studied with fluorescence microscopy. Biophys J 1996; 71: 91-100
90. Klein J. Membrane breakdown in acute and chronic neurodegeneration. Focus on choline-containing phospholipids. J Neural Transm 2000; 107: 1027-1063
91. Kirsch C, Eckert GP, Müller WE. Statin effects on cholesterol microdomains in brain plasma membranes. Biochem Pharmacol 2003; 65: 843-856
92. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of τ phosphorylation in cultured neurons. J Neurochem 2002; 76: 391-400
93. Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-COA reductase activity causes changes in suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Euro J Neurosci 2003; 17: 93-102
94. Müller WE, Kirsch C, Eckert GP. Membrane-disordering effects of β-amyloid peptides. Biochem Soc Trans 2001; 29: 617-623
95. Heiss WD, Hebold T, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz K. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Flow Metabol 1988; 8: 613-617
96. Scheuer K, Rostock A, Bartsch R, Müller WE. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry 1999; 32 (Suppl): 10-16
97. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse rat, and human brain. Biochem Pharmacol 1997; 53: 135-140
98. Hoyer S, Lannert H, Nöldner M, Chatterjee SS. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999; 106: 1171-1188
99. Stoll S, Scheuer K, Pohl O, Müller WE. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 1996; 29: 144-149
100. Watanabe CMH, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci USA 2001; 98: 6577-6580
101. Huri H, Ogwuegbu SO, Boujard N, Drieu D, Papedopulus V. In vivo granulation of the peripheral-type benzodiazepine receptor and glucocorticoid syntheses by the Ginkgo biloba extract 761 and isolated gingkolides. Endocrinology 1996; 137: 5707-5718
102. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. J Amer Med Ass 1997; 278: 1327-1332
103. Sims NR, Bowen DM, Allen SJ, Smith TTC, Neary D, Thomas DJ, Davison AN. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1993; 40: 503-509
104. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998; 393: 373-377
105. Sapolsky RM. The stress of Gulf War syndrome. Nature 1998; 393: 308-309
106. Kammer H von der, Mayhaus M, Albrecht C, Enderich J, Wegner M, Nitsch RM. Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors. J Biol Chem 1998; 273: 14538-14544
107. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001; 300: 157-160
108. Woodruff-Pak DS, Vogel III RW, Wenk GL. Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 2001; 98: 2089-2094
109. Jeyrasasingam G, Yeluashvili M, Quik M. Tacrine, a reversible acetylcholinesterase inhibitor, induces myopathy. NeuroReport 2000; 11: 1173-1176
110. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand Suppl 2000; 176: 60-67
111. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Tansm 1994; 43 (Suppl): 91-104
112. Winblad B, Poritis N. Memantine in severe dementia: results of the M-Best study (Benefit and efficacy in severly demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-146
113. Heidrich A, Rösler M, Riederer P. Pharmakotherapie bei Alzheimer-Demenz: Therapie kognitiver Symptome - neue Studienresultate. Fortschr Neurol Psychiat 1997; 65: 108-121
114. Iqbal K. Neurofibrillary Degeneration: A Promising Target for the Treatment of Alzheimer's disease and other Tauopathies. Seville: Abstract book, p 42, Int. Conf. AD/PD, 2003
115. b Alvarez XA, Lombardi V, Sampedro C, Corzo L, Zas Z, Perez P, Laredo M, Couceiro V, Astoreka I, Varela M, Fernandez-Novoa L, Cacabelos R, Stoeffier A, Moebius HJ. Genotype-Related Reduction of Apoptosis in Alzheimer's disease Patients treated with Memantine. Seville: Abstract book, p 54, Int. Conf. AD/PD, 2003
116. Reisberg B, Stoeffier A, Ferris S, Schmitt F, Doody RS, Moebius HJ. A placebo-controlled study of memantine in advanced Alzheimer's disease. New England J Med 2003; 348: 1333-1341
117. Gerlach M, Youdim MBH, Riederer P. Pharmacology of selegiline. Neurology 1996; 47 (Suppl 3): 2137-2145
118. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630
119. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460-6464
120. Endo A, Hasumi K. Biochemical aspects of HMG CoA reductase inhibitors. Ad Enzyme Regul 1989; 28: 53-64
121. Jick H,Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631
122. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3 methyl-glutaryl Coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443
123. Blennow K, Wallin A. Clinical heterogeneity of probable Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 106-113
124. Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, Runz H, Kühl S, Bertsch T, Bergmann K von, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861
125. Eckert GP, Kirsch C, Müller WE. Differential effects of lovostatin treatment on brain cholesterol levels in normal and ApoE-deficient mice. NeuroReport 2001; 12: 883-887
126. a Simons M, Schwärzler I, Lütjohann D, Bergmann K von, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomised, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350
127. Sjorgren MJC, Gustafsson K, Syversen S, Olsson A, Wallin A, Blennow K. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Seville: Abstract book, p 47, Int. Conf. AD/PD, 2003
128. Yanagisawa K. Cholesterol and Aβ cascade: Pathological implication of Apolipoproteine in Alzheimer's disease. Seville: Abstract book, p 123, Int. Conf. AD/PD, 2003
129. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001; 276: 24985-24990
130. Birge SJ, Mortel KF. Estrogen and the treatment of Alzheimer's disease. Am J Med 1997; 103: 36-45
131. Lannert H, Wirtz P, Schuhmann V, Galmbacher R. Effects of estradiol (β-17) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin. J Neural Transm 1998; 105: 1045-1063
132. McEwen BS. The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metabol 1999; 84: 1790-1797
133. Blum-Degen D, Haas M, Pohli S, Harth S, Riederer P, Götz M. Scavestrogens protect IMR 32 cells from oxidative stress - induced cell death. Toxicol Pharmacol 1998; 152: 49-55
134. Berchtold NC, Kesslak JP, Pike CJ, Adlard PA, Cotman CW. Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur J Neurosci 2001; 14: 1992-2002
135. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer PE, Sheline Y, Luby J, Dagogo-Jack A, Alderson A. Memory improvement following induced hyperinsulinemia in dementia of the Alzheimer type. Neurobiol Aging 1996; 17: 123-130
136. Manning CA, Ragazzino MC, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 1993; 14: 523-528
137. Boyt AA, Taddel K, Hallmayer J, Helmerhorst E, Gandy SE, Craft S, Martins RN. The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 2000; 95: 727-734
138. Löffler T, Lee SK, Nöldner M, Chatterjee SS. Effect of Ginkgo biloba extract (EGb 761) on glucose-metabolic-related markers in streptozotocin-damaged rat brain. J Neural Transm 2001; 108: 457-1474
139. Robinson SR, Münch G. Alzheimer's vaccine: a cure worse than the disease? J Neural Transm 2002; 109: 537-539
140. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002; 415: 462
141. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996; 103: 455-490